Human medicines European public assessment report (EPAR): Aimovig, erenumab, Date of authorisation: 26/07/2018, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Akynzeo, netupitant,palonosetron, Date of authorisation: 27/05/2015, Revision: 20, Status: Authorised

Human medicines European public assessment report (EPAR): Briviact (in Italy: Nubriveo), brivaracetam, Date of authorisation: 13/01/2016, Revision: 27, Status: Authorised

Human medicines European public assessment report (EPAR): Tesavel, sitagliptin, Date of authorisation: 10/01/2008, Revision: 29, Status: Authorised

Human medicines European public assessment report (EPAR): Dupixent, dupilumab, Date of authorisation: 26/09/2017, Revision: 45, Status: Authorised

Clinical investigation of medicinal products in the treatment of Parkinson's disease - Scientific guideline

Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of Parkinson’s disease

Minutes - Management Board meeting: 2 October 2025

Appendix 1: Acceptable intakes established for N-nitrosamines

Stakeholders and Communication